Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE versus KENALOG 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE versus KENALOG 80.
DEXAMETHASONE vs KENALOG-80
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and anti-proliferative effects. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, which reduces prostaglandin and leukotriene synthesis. It also suppresses cytokine production and immune cell migration.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
60 mg (1.5 mL) intramuscularly (deep IM) as a single dose for allergic/ inflammatory conditions; intra-articular or soft tissue injection: 10-40 mg for large joints, 5-25 mg for medium joints, 2.5-10 mg for small joints; intralesional: up to 1 mg per injection site, repeated as needed.
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Terminal elimination half-life: 2–4 hours for triamcinolone acetonide; prolonged in hepatic impairment (up to 6–8 hours).
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine, with minor biliary/fecal elimination (<2%).
Category D/X
Category C
Corticosteroid
Corticosteroid